Treatment with the PCSK9 inhibitor alirocumab reduces the risk of stroke in patients with recent acute coronary syndrome (ACS) and dyslipidaemia despite intensive statin therapy, regardless of their baseline low-density lipoprotein cholesterol (LDL-C) and history of cerebrovascular disease (CeVD), according to the results of the ODYSSEY OUTCOMES trial presented at the 2019 Scientific Sessions of the American Heart Association.
The administration of tranexamic acid within 3 hours of sustaining a traumatic brain injury (TBI) led to a reduction in mortality risk, highlighting the importance of early treatment in this setting, the CRASH*-3 trial has shown.
Roxadustat improves haemoglobin levels vs placebo and epoetin alfa, with similar safety profile, in 8,000 patients with chronic kidney disease (CKD)-related anaemia on- and off-dialysis, according to a pooled efficacy and CV safety analyses of roxadustat, spanning over 13,000 patient exposure years.
Endovascular treatment for ischaemic stroke produces improvements in functional outcome and other clinical, imaging and safety outcome measures. The treatment effect is similar between men and women, with the latter even having more years of healthy life, as shown in the results of two recent studies.
A retrospective, multicentre cohort study has shown that the safety profile of thrombectomy in childhood stroke does not differ from the safety profile in randomized clinical trials for adults, supporting clinicians’ off-label practice of thrombectomy in paediatric patients, in the absence of high-level evidence.
Measuring heart rate variability (HRV) using a wearable echocardiography (ECG) device shows promise in detecting seizures, including the nonconvulsive episodes, proving to have high sensitivity and low false alarm rate during the night, according to data from a phase II validation study.
The 30-day mortality rates among patients undergoing transcatheter aortic valve replacement (TAVR) have decreased by more than half over the last decade, with significant differences between genders, a CENTER* collaboration analysis has shown.
Admitted patients with a cerebrovascular accident (stroke) or transient ischaemic attack (TIA) who received pharmacist intervention in the stroke prevention clinic (SPC) are less likely to be readmitted and more likely to show improvement in surrogate markers, such as blood pressure (BP) and haemoglobin (Hb)A1c, a study has shown.